GT Biopharma Stock (NASDAQ:GTBP)


OwnershipFinancialsChart

Previous Close

$2.81

52W Range

$1.72 - $10.66

50D Avg

$2.78

200D Avg

$2.99

Market Cap

$7.24M

Avg Vol (3M)

$355.79K

Beta

0.57

Div Yield

-

GTBP Company Profile


GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

Mar 27, 2018

Website

GTBP Performance


GTBP Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-13.58M$-21.26M$-57.52M
Net Income$-7.60M$-20.50M$-58.69M
EBITDA$-13.58M$-20.96M$-57.48M
Basic EPS$-5.64$-0.64$-2.08
Diluted EPS$-5.64$-0.64$-2.08

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 21Aug 13, 21 | 1:11 PM

Peer Comparison


TickerCompany
REVBRevelation Biosciences, Inc.
SRZNSurrozen, Inc.
BDRXBiodexa Pharmaceuticals Plc
VCNXVaccinex, Inc.
MNPRMonopar Therapeutics Inc.
PULMPulmatrix, Inc.
SABSSAB Biotherapeutics, Inc.
VRPXVirpax Pharmaceuticals, Inc.
CVKDCadrenal Therapeutics, Inc. Common Stock
QNRXQuoin Pharmaceuticals, Ltd.
VRAXVirax Biolabs Group Limited
ALLRAllarity Therapeutics, Inc.
NRBONeuroBo Pharmaceuticals, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
AKTXAkari Therapeutics, Plc
PRAXPraxis Precision Medicines, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
TARAProtara Therapeutics, Inc.